Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity

Okumura, Hirokazu; Iuchi, Kazuyuki; Yoshida, Takashi; Nakamura, Shinobu; Takeshima, Minoru; Takamatsu, Hideyuki; Ikeno, Atsuhisa; Usuda, Kazuo; Ishikawa, Tadao; Ohtake, Shigeki; Matsuda, Tamotsu

doi:10.1159/000046508

Cited by 96 publications

(55 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies concluded that there is an association between LV dysfunction and increased natriuretic peptide concentrations (16 -21 ). Only a few anecdotal reports (22)(23)(24)(25) exist on the potential role of ANP and/or BNP as markers useful for detecting subclinical cardiac dysfunction, whereas no reports have been published on the role of NT-proBNP.…”

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

Sandri¹,

Salvatici²,

Cardinale³

et al. 2005

Clinical Chemistry

214

140

View full text Add to dashboard Cite

Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NTproBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year followup. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values

show abstract

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

Sandri¹,

Salvatici²,

Cardinale³

et al. 2005

Clinical Chemistry

214

140

View full text Add to dashboard Cite

show abstract

“…Some authors studied the association and relationship between natriuretic peptides and diastolic LV dysfunction, and others simply checked systolic LV function. However, only a few studies 55,[63][64][65][66][67] evaluated the potential predictive value of natriuretic peptide concentrations to detect the ongoing development of cardiac dysfunction.…”

Section: Natriuretic Peptides As Markers Of Ct-induced Cardiotoxicitymentioning

confidence: 99%

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracyclinebased chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. Methods and Results. Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined. Conclusions. This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

show abstract

“…Furthermore, this assay can add prognostic information for newly diagnosed patients more effectively than echocardiography and can be useful in designing therapeutic strategies and monitoring response (74 ). Another example is the possibility, mainly by BNP assay, of identifying HF related to anthracycline cardiotoxicity (66,(75)(76)(77)(78).…”

Section: Diagnostic Accuracy Of Cnh Assays In Patients With Acute Myomentioning

confidence: 99%

Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review

2004

View full text Add to dashboard Cite

Background:The pathophysiologic and clinical relevance of cardiac natriuretic hormone (CNH) assays has been investigated in numerous experimental and clinical studies. Authors have sought to evaluate the diagnostic accuracy and prognostic relevance of the measurement of CNHs according to evidence-based laboratory medicine principles. Methods: In June 2003, we ran a computerized literature search on National Library of Medicine using keywords "ANP" and "BNP" and found more than 12 300 and 1200 articles, respectively. A more refined search with keywords "ANP or BNP assay" extracted ϳ7000 and 800 articles, respectively. Only studies specifically designed to evaluate the diagnostic accuracy and prognostic relevance of CNH measurements were selected from this huge mass of articles to be discussed in this review. Content: Several studies suggested that CNH assays may be clinically useful for the screening and classification of patients with heart failure, as a prognostic marker in cardiovascular disease, in the follow-up of patients with heart failure, and because they may reduce the need for further cardiac investigation. However, it is difficult to compare even the best-designed studies because not only did the authors evaluate different populations, they also used different gold standards. Conclusions: CNH assays and conventional diagnostic work-ups provide complementary information for evaluation of the presence and severity of cardiac dysfunction and clinical disease. Several aspects of CNH assays are still to be elucidated, and further work is needed to

show abstract

Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity

Cited by 96 publications

References 18 publications

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review

Contact Info

Product

Resources

About